News
Conference Coverage
‘We finally made it’: Amivantamab comes of age in NSCLC
Data from three trials with amivantamab in advanced EGFR-mutant NSCLC have yielded “exciting” results with experts hailing the drug as standard of...
Latest News
Induction chemotherapy in first line improves survival for locally advanced cervical cancer
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...
News
FDA warns of hidden ingredients in arthritis, pain products
“I don’t know if this was intentional, but it seems suspicious that a product marketed to reduce joint pain and inflammation contains prescription...
Conference Coverage
Ocular MALT lymphoma: Radiation reduces relapse
Mortality rates from early-stage ocular MALT lymphoma are low, with relapse rates lowered by radiation therapy.
News
Massive databases unleash discovery, but not so much in the U.S.
Vast medical databases have connected dots where smaller randomized trials could not. But the United States has a long way to go.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Conference Coverage
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...
Conference Coverage
‘Why did I choose this?’ Tackling burnout in oncology
Building a sustainable oncology workforce will not be easy, but improving staffing shortages and integrating resilience training can help, experts...
News
FDA OKs ivosidenib for IDH1-mutated myelodysplastic syndromes
For adults with a rare form of myelodysplastic syndromes, the FDA has approved a targeted therapy called ivosidenib.
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...